Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
Bayer and Lilly make radioligand progress
First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.
Pfizer shuffles its deck post-Seagen
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
ASCO-GU – Opdivo's approval might have scuppered Keynote-123
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
ASCO-GI – some shine comes off Astra’s Emerald
The first-line liver cancer Emerald-1 trial is positive, but only up to a point.
